bluebird bio Inc BLUE.OQ BLUE.O is expected to show a rise in quarterly revenue when it reports results on May 7 (estimated) for the period ending March 31 2025
The Somerville Massachusetts-based company is expected to report a 104.1% increase in revenue to $37.9 million from $18.57 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for bluebird bio Inc is for a loss of $3.69 per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had risen by about 0.6% in the last three months.
Wall Street's median 12-month price target for bluebird bio Inc is $8.00, above its last closing price of $3.95.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -5.13 | -5.98 | -2.95 | Beat | 50.6 |
Sep. 30 2024 | -6.65 | -7.29 | -6.20 | Beat | 14.9 |
Jun. 30 2024 | -9.96 | -8.33 | -8.40 | Missed | -0.8 |
Mar. 31 2024 | -8.83 | -8.81 | -7.20 | Beat | 18.3 |
Dec. 31 2023 | -13.01 | -13.24 | -15.60 | Missed | -17.8 |
Sep. 30 2023 | -13.45 | -13.50 | -13.20 | Beat | 2.2 |
Jun. 30 2023 | -14.37 | -14.31 | -13.40 | Beat | 6.4 |
Mar. 31 2023 | -5.37 | -7.40 | 4.20 | Beat | 156.8 |
This summary was machine generated May 5 at 13:07 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。